Artificial Pancreas Technology for Managing Diabetes in Emergency Situations

For individuals living with type 1 diabetes—and increasingly for those with insulin-dependent type 2 diabetes—maintaining blood glucose within a safe range is a constant, high-stakes balancing act. The introduction of artificial pancreas technology, also known as automated insulin delivery (AID) systems, has shifted this burden from manual, reactive management to continuous, automated control. In routine daily life these systems improve time-in-range and reduce hypoglycemic events, but their value becomes even more pronounced during emergencies. When stress, illness, or other unexpected events destabilize glucose levels, an artificial pancreas can act as a resilient safety net, buying precious minutes that can prevent severe complications.

What Is an Artificial Pancreas?

An artificial pancreas is a closed-loop system that integrates a continuous glucose monitor (CGM), an insulin pump, and a control algorithm to automatically regulate blood glucose. The system mimics the endocrine function of a healthy pancreas, which responds to rising glucose with insulin secretion and to falling glucose with glucagon release. While most current commercial systems deliver only insulin, research is advancing toward dual-hormone devices that also administer glucagon to prevent hypoglycemia. The device reduces the need for fingerstick checks, manual bolus calculations, and the constant vigilance that characterizes conventional diabetes management.

The concept was first outlined in the 1970s, but practical implementations only became viable in the 2010s due to improvements in CGM accuracy and algorithm computing power. The U.S. Food and Drug Administration (FDA) has now approved several hybrid closed-loop systems for people with type 1 diabetes aged 2 years and older. These systems are sometimes referred to as a “semi-autonomous pancreas” because they still require user input for meals and exercise, but they automatically adjust basal insulin delivery to keep glucose levels stable overnight and between meals.

Core Components of the System

  • Continuous Glucose Monitor (CGM): A small sensor inserted under the skin measures interstitial glucose every 1–5 minutes. Modern CGMs such as Dexcom G6/G7 and Abbott FreeStyle Libre 3 deliver accuracy within 8–10% of venous blood glucose and require no fingerstick calibration. Some newer models can also function as stand-alone emergency monitoring devices, sending alerts directly to a smartphone or caregiver.
  • Insulin Pump: A wearable device that infuses rapid-acting insulin through a small cannula. Pumps like the Tandem t:slim X2 or Omnipod 5 can be controlled by the algorithm and, in some models, receive direct commands from the CGM. The pump’s delivery precision is critical during emergencies because even small dose errors can have outsized effects when the body is under stress.
  • Control Algorithm: The software brain of the system. It receives CGM data and applies predictive models to decide how much basal insulin to deliver, when to suspend delivery for safety, and in advanced systems, when to deliver correction boluses automatically. Algorithms use proportional-integral-derivative (PID) control, model predictive control (MPC), or fuzzy logic. Each approach has trade-offs in responsiveness versus stability, which becomes particularly important during rapid glucose fluctuations seen in acute illness.
  • Optional Dual-Hormone Component: Some experimental systems add a glucagon pump. Glucagon raises blood glucose rapidly, allowing the system to counteract insulin overdoses or unexpected hypoglycemia. While not yet commercialized in the U.S., dual-hormone prototypes have shown superior hypoglycemia prevention in clinical trials, especially during exercise and fasting—two states often encountered in emergency settings.

Why Emergency Situations Demand Automated Control

During emergencies—whether a severe hypoglycemia event, diabetic ketoacidosis (DKA), a sudden illness with vomiting, a natural disaster, or surgery under anesthesia—the body’s glucose dynamics can change unpredictably. Stress hormones such as cortisol and adrenaline increase insulin resistance, causing hyperglycemia, while reduced food intake, delayed gastric emptying, or medication interactions can push glucose dangerously low. In these scenarios, manual management tends to lag behind the body’s needs, increasing risk.

Severe Hypoglycemia and Hypoglycemia Unawareness

Hypoglycemia unawareness, a condition in which a person no longer feels the early warning signs of low blood sugar, affects roughly 20–30% of people with long-standing type 1 diabetes. An artificial pancreas can detect a rapid downward trend in glucose seconds before symptoms become dangerous. The algorithm immediately reduces or suspends insulin delivery and, in dual-hormone systems, administers a micro-dose of glucagon to preempt a severe event. This automated response keeps the person conscious and avoids the need for emergency glucagon injections or paramedic intervention. In a hospital setting, where patients may be sedated or otherwise unable to communicate symptoms, closed-loop systems provide an extra layer of protection that manual protocols cannot match.

Diabetic Ketoacidosis (DKA) and Hyperglycemic Crises

Illness, pump failure, or missed injections often precipitate DKA, a life-threatening condition of high glucose combined with ketones. An artificial pancreas can help prevent the cascade by continuously adjusting insulin upward as glucose rises, reducing the time spent in hyperglycemic range. Some algorithms also integrate ketone trend simulation to increase the urgency of insulin delivery. In one study published in Diabetes Care, artificial pancreas use reduced the incidence of ketosis by nearly 60% compared with standard pump therapy. (Link to study) During acute infections like COVID-19, where insulin resistance can spike dramatically, closed-loop systems have been shown to maintain better glycemic control than conventional sliding-scale insulin regimens.

Use During Surgery and Anesthesia

Perioperative glycemic control has long been a challenge, with both hypo- and hyperglycemia linked to increased complications—wound infection, prolonged hospital stay, and even mortality. Using an artificial pancreas during surgery allows continuous adaptive insulin delivery without the need for intraoperative fingerstick checks. Pilot studies at academic medical centers showed that closed-loop insulin delivery maintained glucose within target range (70–180 mg/dL) for over 85% of the operative time, compared to about 50% with manual protocols. (PubMed reference) The technology is particularly valuable in procedures lasting several hours, where stress hormone levels can fluctuate unpredictably. Some hospitals are now exploring dedicated closed-loop protocols for diabetic patients undergoing cardiac or bariatric surgery.

Natural Disasters and Disrupted Care

When hurricanes, wildfires, or other emergencies cut off access to pharmacies, electricity, and clean water, insulin-dependent individuals face immediate peril. An artificial pancreas may provide a buffer: its automated control reduces the cognitive burden on a person who is stressed, dehydrated, and possibly injured. Moreover, some algorithms can adapt to missed doses or sensor drift longer than open-loop pumps. Emergency planners are now including AID systems in their disaster preparedness guidelines, noting that patients on closed-loop therapy should keep backup supplies (CGM sensors, pump batteries, and manual insulin syringes) in their go-bag. In situations where evacuation is chaotic, the ability of the system to continue working with minimal user input can make the difference between safe evacuation and a medical crisis on the road.

Current Commercial Systems and Their Emergency Capabilities

Several artificial pancreas systems have received FDA approval and are available in the U.S. Each has unique strengths relevant to emergency management:

  • Medtronic MiniMed 780G: The 780G offers SmartGuard technology with an auto-correction bolus feature. In emergencies it can automatically deliver up to 2.0 units of correction every 5 minutes when glucose exceeds 120 mg/dL. The system suspends delivery below 70 mg/dL and can be set to suspend before a predicted low threshold. Its sensor, the Guardian 4, does not require fingerstick calibration—an important advantage when test strips may be unavailable.
  • Tandem Diabetes Care Control-IQ: This algorithm, integrated with the t:slim X2 pump and Dexcom G6 CGM, uses predictive low-glucose suspend and automatic boluses. During exercise or illness, users can set temporary targets (e.g., 140–160 mg/dL) to reduce hypoglycemia risk. Clinical data from the DCLP3 trial showed that Control-IQ users experienced 42% less time below 70 mg/dL overall. The system also features a sleep activity mode that tightens control overnight, which is beneficial for hospitalized patients.
  • Insulet Omnipod 5: The first tubeless closed-loop system. Its algorithm adjusts basal rates every 5 minutes and can correct high glucose. The fact that the pump is pod-shaped and waterproof makes it advantageous in emergency settings where patients might be in damp conditions or need to move quickly. The absence of tubing also reduces the risk of dislodgment during physical trauma or evacuation.

While these systems are a major advance, none currently include glucagon, and their performance depends on sensor accuracy. During extreme physical stress, such as a septic infection, sensor error may increase due to dehydration or rapid fluid shifts. Users are advised to confirm sensor readings with a blood glucose meter when symptoms seem discordant. Emergency medical personnel should be trained to recognize that a patient on AID therapy may have different glucose dynamics than a patient on conventional insulin regimens.

Affordability and Access as a Barrier in Emergencies

Insurance coverage, out-of-pocket costs, and distribution logistics remain significant hurdles. The cost of a full artificial pancreas setup—pump, CGM, and replacement supplies—can exceed $5,000–$8,000 per year without insurance. For uninsured individuals or those in crisis, access to this technology is practically nonexistent. Patient advocacy groups like JDRF and the American Diabetes Association (ADA) are lobbying for expanded Medicaid coverage and disaster stockpiling of closed-loop systems, but policies lag behind clinical evidence. Emergency departments and disaster relief teams rarely stock AID systems, leaving patients to rely on older, less effective manual methods during crises. The ADA provides resources on technology access, but many communities lack the infrastructure to distribute these devices in emergencies.

Future Directions: Toward True Autonomy in Crisis

Dual-Hormone and Multi-Hormone Systems

Adding glucagon and, potentially, pramlintide (to slow gastric emptying and reduce post-meal spikes) would transform the artificial pancreas into a more complete metabolic regulator. The Beta Bionics iLet Bionic Pancreas, which received FDA clearance for insulin-only mode, is pursuing a dual-hormone version. In a randomized controlled trial, the iLet dual-hormone system reduced hypoglycemia during exercise by 70% compared to insulin-only. This capability would be invaluable during emergencies when oral carbohydrate intake may be impossible—for instance, in a patient with altered mental status or facial trauma. The glucagon component also provides a safety buffer against insulin stacking, which can occur when paramedics or hospital staff are unaware of recent system delivery.

AI-Enhanced Predictive Algorithms

Machine learning models can analyze historical data—meal patterns, activity levels, sick days—to preempt glycemic excursions. For example, an algorithm trained on past surgical patients could anticipate insulin resistance patterns during an upcoming operation and automatically adjust settings hours before the procedure. Researchers are also developing “emotion-aware” algorithms that detect stress from heart rate variability and adjust insulin delivery accordingly. These AI-driven systems could categorize emergency severity in real time, downgrading insulin delivery during acute stress to prevent hypoglycemia and upgrading it when hyperglycemia dominates.

Remote Monitoring and Telemedicine Integration

In an emergency, a caregiver or emergency medical services (EMS) team could access the patient’s glucose data in real time via smartphone integration. Companies like Dexcom already allow follower apps. Future artificial pancreas systems may transmit both glucose and pump status to a central command center in a hospital or ambulance. The FDA has encouraged interoperability standards to make this data flow seamless. For example, a 911 dispatcher could see that a disoriented patient’s glucose is trending low and instruct responders to administer glucagon before arrival. Such integration could reduce emergency department visits and improve survival probabilities for patients in remote areas.

Closing the Loop for Type 2 Diabetes

Over 30 million Americans have type 2 diabetes, and many require intensive insulin therapy during hospitalization, surgery, or stress. Several studies are testing automated insulin delivery in type 2 patients; early results show similar benefits in reducing hypoglycemia and improving time-in-range. If affordable, easy-to-use closed-loop systems become available for type 2 diabetes, the potential impact in emergency medicine would be massive—especially for the elderly, who are more prone to severe hypoglycemia. Some health systems are already piloting simplified versions of AID for inpatients with type 2 diabetes, using protocols that require minimal nursing intervention.

Conclusion

Artificial pancreas technology has evolved from a research concept to a practical, life-saving tool that meaningfully reduces the burden of diabetes management. In emergency situations—whether due to acute illness, surgery, or environmental disruption—the automated, continuous oversight provided by these systems can be the difference between a manageable event and a life-threatening crisis. While challenges surrounding cost, sensor accuracy, and access remain, the trajectory of innovation is clear: future systems will become smarter, more resilient, and increasingly autonomous. For the millions of people depending on insulin, the artificial pancreas is not merely a convenience—it is an imperative component of emergency preparedness and safe, modern diabetes care.